Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00461981 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate Immune Responses of FluMist®
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT00461981: Completed Phase 2 study, sponsored by MedImmune.
NCT00461981 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 101 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00461981, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
Primary Outcome
The percentage of baseline seronegative subjects (baseline titer of 4 or less) achieving a 4 or more fold increase in titer from baseline at Post Dose 1 (28-42 days after Dose 1) for the H1N1 /wt A/New Caledonia/20/99 antigenically matched influenza strain
Interventions
- BIOLOGICAL TIV, Trivalent Inactivated Influenza Virus Vaccine
- BIOLOGICAL FluMist, Influenza Virus Vaccine Live
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT00461981 record still lists
NCT00461981 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 2 interventions - of which TIV, Trivalent Inactivated Influenza Virus Vaccine is the first listed.
NCT00461981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00461981 about?
NCT00461981 is a clinical study titled "A Phase 2 Study to Evaluate Immune Responses of FluMist®". The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
What is the current status of trial NCT00461981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2007-05. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00461981?
The interventions under investigation include: TIV, Trivalent Inactivated Influenza Virus Vaccine (BIOLOGICAL), FluMist, Influenza Virus Vaccine Live (BIOLOGICAL).
Who is sponsoring clinical trial NCT00461981?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00461981's enrollment target sits among peer trials
101 672nd of 2000 higher than 1,329 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia